|
US7794729B2
(en)
*
|
1994-11-08 |
2010-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for immunotherapy of cancer
|
|
US7820180B2
(en)
*
|
2004-09-24 |
2010-10-26 |
The Trustees Of The University Of Pennsylvania |
Listeria-based and LLO-based vaccines
|
|
US8791237B2
(en)
|
1994-11-08 |
2014-07-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of non-hodgkins lymphoma
|
|
WO2001072329A1
(en)
*
|
2000-03-29 |
2001-10-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing immunogenicity of antigens
|
|
US8956621B2
(en)
|
1994-11-08 |
2015-02-17 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical dysplasia
|
|
US8114414B2
(en)
*
|
1994-11-08 |
2012-02-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of cervical cancer
|
|
US6977074B2
(en)
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
|
US20030138808A1
(en)
*
|
1998-02-19 |
2003-07-24 |
Simard John J.L. |
Expression vectors encoding epitopes of target-associated antigens
|
|
US20030176663A1
(en)
*
|
1998-05-11 |
2003-09-18 |
Eidgenossische Technische Hochscule |
Specific binding molecules for scintigraphy
|
|
JP2003524018A
(ja)
*
|
2000-02-24 |
2003-08-12 |
アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ |
フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
|
|
US9012141B2
(en)
*
|
2000-03-27 |
2015-04-21 |
Advaxis, Inc. |
Compositions and methods comprising KLK3 of FOLH1 antigen
|
|
US20030215425A1
(en)
*
|
2001-12-07 |
2003-11-20 |
Simard John J. L. |
Epitope synchronization in antigen presenting cells
|
|
CN1246333C
(zh)
*
|
2000-09-07 |
2006-03-22 |
舍林股份公司 |
EDb－纤粘连蛋白结构域(II)的受体
|
|
US8771702B2
(en)
|
2001-03-26 |
2014-07-08 |
The Trustees Of The University Of Pennsylvania |
Non-hemolytic LLO fusion proteins and methods of utilizing same
|
|
US7700344B2
(en)
*
|
2001-03-26 |
2010-04-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for enhancing the immunogenicity of antigens
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
WO2003034903A2
(en)
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
US8637305B2
(en)
*
|
2001-11-07 |
2014-01-28 |
Mannkind Corporation |
Expression vectors encoding epitopes of target-associated antigens and methods for their design
|
|
WO2003068800A2
(en)
*
|
2002-02-13 |
2003-08-21 |
Ludwig Institute For Cancer Research |
Isolated peptides which bind to hla molecules and uses thereof
|
|
US20030228308A1
(en)
*
|
2002-06-05 |
2003-12-11 |
Yi Zhang |
Isolated peptides which bind to HLA-Cw6 molecules and uses thereof
|
|
WO2004022709A2
(en)
*
|
2002-09-06 |
2004-03-18 |
Mannkind Corporation |
Epitope sequences
|
|
EP1587837B1
(en)
*
|
2003-01-28 |
2012-06-13 |
Proscan RX Pharma Inc. |
Epitope sequences for prostate cancer diagnosis and treatment
|
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
|
GB0313132D0
(en)
*
|
2003-06-06 |
2003-07-09 |
Ich Productions Ltd |
Peptide ligands
|
|
AU2004249254B2
(en)
*
|
2003-06-17 |
2010-07-08 |
Mannkind Corporation |
Combinations of tumor-associated antigens for the treatment of various types of cancers
|
|
DE602004028468D1
(de)
|
2003-06-17 |
2010-09-16 |
Mannkind Corp |
Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
|
|
DE602004031116D1
(de)
|
2003-07-22 |
2011-03-03 |
Ludwig Inst For Cancer Res New York |
Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
EP1773402A2
(en)
*
|
2004-06-17 |
2007-04-18 |
Mannkind Corporation |
Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
|
|
US8202841B2
(en)
|
2004-06-17 |
2012-06-19 |
Mannkind Corporation |
SSX-2 peptide analogs
|
|
US20060159689A1
(en)
*
|
2004-06-17 |
2006-07-20 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
US20060008468A1
(en)
*
|
2004-06-17 |
2006-01-12 |
Chih-Sheng Chiang |
Combinations of tumor-associated antigens in diagnostics for various types of cancers
|
|
US7858743B2
(en)
|
2004-09-09 |
2010-12-28 |
Ludwig Institute For Cancer Research |
SSX-4 peptides presented by HLA class II molecules
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
US20060165711A1
(en)
*
|
2004-12-29 |
2006-07-27 |
Bot Adrian I |
Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
|
|
AU2005321898B2
(en)
*
|
2004-12-29 |
2012-07-19 |
Mannkind Corporation |
Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
|
|
EP1838342A2
(en)
*
|
2004-12-29 |
2007-10-03 |
Mannkind Corporation |
Methods to bypass cd+4 cells in the induction of an immune response
|
|
EP1838338A2
(en)
|
2004-12-29 |
2007-10-03 |
Mannkind Corporation |
Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
|
|
JP2008527001A
(ja)
*
|
2005-01-13 |
2008-07-24 |
ザ ジョンズ ホプキンス ユニバーシティー |
前立腺幹細胞抗原ワクチンおよびその使用
|
|
NZ564359A
(en)
*
|
2005-06-17 |
2011-09-30 |
Mannkind Corp |
Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
|
|
MX2007015933A
(es)
|
2005-06-17 |
2008-04-21 |
Mannkind Corp |
Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
|
|
CN101687020A
(zh)
*
|
2005-06-17 |
2010-03-31 |
曼康公司 |
用于癌症的多价引发-和-增强免疫治疗剂
|
|
JP4945444B2
(ja)
*
|
2005-06-29 |
2012-06-06 |
株式会社グリーンペプタイド |
Ｈｌａ−ａ３スーパータイプアレル分子陽性前立腺癌患者に対する癌ワクチン候補となる前立腺関連蛋白由来ペプチド
|
|
WO2007109321A2
(en)
|
2006-03-20 |
2007-09-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
WO2008008541A2
(en)
*
|
2006-07-14 |
2008-01-17 |
Mannkind Corporation |
Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
|
|
EP2129389B1
(en)
|
2007-02-15 |
2014-10-08 |
MannKind Corporation |
A method for enhancing t cell response
|
|
WO2008118017A2
(en)
*
|
2007-03-26 |
2008-10-02 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Prame derived peptides and immunogenic compositions comprising these
|
|
MX2009012635A
(es)
*
|
2007-05-23 |
2012-09-13 |
Mannkind Corp |
Vectores multicistronicos y metodos para su diseño.
|
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
|
US8940298B2
(en)
|
2007-09-04 |
2015-01-27 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
|
|
ES2623447T3
(es)
*
|
2007-12-19 |
2017-07-11 |
Rhovac Aps |
Inmunoterapia basada en RhoC
|
|
US8253725B2
(en)
*
|
2007-12-28 |
2012-08-28 |
St. Jude Medical, Atrial Fibrillation Division, Inc. |
Method and system for generating surface models of geometric structures
|
|
US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
|
US20110129499A1
(en)
|
2008-05-19 |
2011-06-02 |
Paulo Maciag |
Dual delivery system for heterologous antigens
|
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
|
US10024868B2
(en)
*
|
2009-06-09 |
2018-07-17 |
Vaxon Biotech |
Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy
|
|
CA2809819A1
(en)
|
2009-09-09 |
2011-03-17 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
AU2010310468A1
(en)
|
2009-10-23 |
2012-05-24 |
Mannkind Corporation |
Cancer immunotherapy and method of treatment
|
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
|
CN102869682B
(zh)
|
2009-11-18 |
2016-10-19 |
曼康公司 |
单克隆抗体及其诊断用途
|
|
CA2836117C
(en)
|
2009-12-10 |
2017-08-15 |
Ottawa Hospital Research Institute |
Oncolytic rhabdovirus
|
|
SE535982C2
(sv)
*
|
2009-12-15 |
2013-03-19 |
Theravac Pharmaceuticals Ab |
Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
|
|
EP2356998A1
(en)
*
|
2010-02-17 |
2011-08-17 |
Université de Liège |
A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein
|
|
DK2528625T3
(da)
|
2010-04-15 |
2013-10-14 |
Spirogen Sarl |
Pyrrolobenzodiazepiner og konjugater deraf
|
|
BR112012030311A2
(pt)
|
2010-06-08 |
2017-01-24 |
Genentech Inc |
anticorpo
|
|
US9226958B2
(en)
|
2010-10-01 |
2016-01-05 |
University Of Georgia Research Foundation, Inc. |
Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
|
JP5889912B2
(ja)
|
2010-11-17 |
2016-03-22 |
ジェネンテック， インコーポレイテッド |
アラニニルメイタンシノール抗体コンジュゲート
|
|
AU2012229218B2
(en)
|
2011-03-11 |
2017-03-02 |
Advaxis, Inc. |
Listeria-based adjuvants
|
|
KR101992502B1
(ko)
|
2011-05-12 |
2019-06-24 |
제넨테크, 인크. |
프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
|
|
GB201114919D0
(en)
*
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
|
JP6104257B2
(ja)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピンおよびそのコンジュゲート
|
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
|
CN104411327A
(zh)
|
2012-03-12 |
2015-03-11 |
阿德瓦希斯公司 |
李斯特菌疫苗治疗以后的抑制细胞功能抑制
|
|
AU2013243948A1
(en)
*
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
JP6378172B2
(ja)
|
2012-05-22 |
2018-08-22 |
アメリカ合衆国 |
マウス抗ｎｙ−ｅｓｏ−１ｔ細胞受容体
|
|
EP3795215A1
(en)
|
2012-05-30 |
2021-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Target tissue-specific antigen-binding molecule
|
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP2906250B1
(en)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Pyrrolobenzodiazepine-anti-psma antibody conjugates
|
|
ES2649990T3
(es)
|
2012-10-12 |
2018-01-16 |
Medimmune Limited |
Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
|
|
US10751346B2
(en)
|
2012-10-12 |
2020-08-25 |
Medimmune Limited |
Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
|
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
US10695433B2
(en)
|
2012-10-12 |
2020-06-30 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
DK2906298T3
(en)
|
2012-10-12 |
2018-12-17 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
AU2013328625B2
(en)
|
2012-10-12 |
2016-12-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
CN105246894A
(zh)
|
2012-12-21 |
2016-01-13 |
斯皮罗根有限公司 |
用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
|
|
CN105189507A
(zh)
|
2012-12-21 |
2015-12-23 |
斯皮罗根有限公司 |
吡咯并苯并二氮杂卓及其结合物
|
|
CA2901501C
(en)
|
2013-02-21 |
2023-03-07 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Vaccine composition
|
|
NZ710746A
(en)
|
2013-03-13 |
2018-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CA2905181C
(en)
|
2013-03-13 |
2020-06-02 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
|
|
SG11201507214SA
(en)
|
2013-03-13 |
2015-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2014207708A2
(en)
|
2013-06-28 |
2014-12-31 |
Auckland Uniservices Limited |
Amino acid and peptide conjugates and conjugation process
|
|
ES2656474T3
(es)
*
|
2013-07-05 |
2018-02-27 |
Arla Foods Amba |
Osteopontina láctea de origen mamífero para potenciar la capacidad de respuesta inmune
|
|
EP3033111B1
(en)
|
2013-08-12 |
2019-03-13 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3054986B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
US10010624B2
(en)
|
2013-10-11 |
2018-07-03 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
|
TWI853985B
(zh)
|
2013-12-04 |
2024-09-01 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
|
BR112016013258A2
(pt)
|
2013-12-16 |
2018-01-16 |
Genentech Inc |
composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
|
|
KR20170042495A
(ko)
|
2013-12-16 |
2017-04-19 |
제넨테크, 인크. |
펩티드모방체 화합물 및 그의 항체-약물 접합체
|
|
JP6671292B2
(ja)
|
2013-12-16 |
2020-03-25 |
ジェネンテック， インコーポレイテッド |
ペプチド模倣化合物及びその抗体−薬物コンジュゲート
|
|
KR101503341B1
(ko)
*
|
2014-03-12 |
2015-03-18 |
국립암센터 |
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
WO2016040825A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
|
MX2017003123A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos y conjugados modificados geneticamente con cisteina.
|
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
US20160074527A1
(en)
|
2014-09-17 |
2016-03-17 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
|
AU2015352545B2
(en)
|
2014-11-25 |
2020-10-15 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
MX2017007169A
(es)
|
2014-12-03 |
2018-05-02 |
Genentech Inc |
Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
|
|
BR112017013574A2
(pt)
|
2014-12-23 |
2018-03-06 |
Verdon Daniel |
conjugados de aminoácido e peptídeo e usos dos mesmos
|
|
CA2973109A1
(en)
|
2015-01-09 |
2016-07-14 |
Etubics Corporation |
Methods and compositions for ebola virus vaccination
|
|
KR102193635B1
(ko)
|
2015-01-09 |
2020-12-21 |
이투빅스 코포레이션 |
복합 면역요법을 위한 방법 및 조성물
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
WO2016172249A1
(en)
|
2015-04-20 |
2016-10-27 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
CA2996902C
(en)
|
2015-10-02 |
2020-06-02 |
Genentech, Inc. |
Pyrrolobenzodiazepine antibody drug conjugates and methods of use
|
|
EP3362100B1
(en)
|
2015-10-16 |
2022-06-22 |
Genentech, Inc. |
Hindered disulfide drug conjugates
|
|
EP3365025B1
(en)
|
2015-10-20 |
2020-07-15 |
Genentech, Inc. |
Calicheamicin-antibody-drug conjugates and methods of use
|
|
CN106610423A
(zh)
*
|
2015-10-26 |
2017-05-03 |
复旦大学 |
评价疫苗疗效的细胞免疫学检测试剂盒及其储存方法
|
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
EP3419962A4
(en)
|
2016-02-26 |
2020-03-11 |
Auckland Uniservices Limited |
CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD
|
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
JP2019520332A
(ja)
*
|
2016-05-23 |
2019-07-18 |
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ |
Ｃｍｖエピトープ
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
MX375569B
(es)
|
2017-02-08 |
2025-03-04 |
Adc Therapeutics Sa |
Conjugados de pirrolobenzodiazepinas y anticuerpos
|
|
PT3612537T
(pt)
|
2017-04-18 |
2022-08-29 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina
|
|
ES2977788T3
(es)
|
2017-04-20 |
2024-08-30 |
Adc Therapeutics Sa |
Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco
|
|
MX2019015042A
(es)
|
2017-06-14 |
2020-08-06 |
Adc Therapeutics Sa |
Regimen de dosificacion.
|
|
CR20200059A
(es)
|
2017-07-07 |
2020-06-01 |
Immatics Biotechnologies Gmbh |
Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres
|
|
CN108503689B
(zh)
*
|
2017-07-10 |
2019-12-31 |
昆明医科大学第一附属医院 |
一种抗血小板聚集的多肽km6
|
|
DK3668874T3
(da)
|
2017-08-18 |
2022-02-14 |
Medimmune Ltd |
Pyrrolobenzodiazepin-konjugater
|
|
IL273387B2
(en)
|
2017-09-20 |
2023-10-01 |
Ph Pharma Co Ltd |
Thylanstatin analogs
|
|
US11192943B2
(en)
*
|
2017-09-30 |
2021-12-07 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Protein binding to fibronectin B domain
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
CN110343167B
(zh)
*
|
2018-04-03 |
2022-10-28 |
香雪生命科学技术（广东）有限公司 |
识别ssx2抗原短肽的t细胞受体
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EP3835321A4
(en)
|
2018-08-10 |
2022-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
CN110950949B
(zh)
*
|
2018-09-26 |
2022-04-05 |
香雪生命科学技术（广东）有限公司 |
一种识别ssx2抗原的t细胞受体
|
|
JP7708662B2
(ja)
|
2018-10-24 |
2025-07-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
コンジュゲート化された化学的分解誘導物質および使用方法
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
|
KR102084912B1
(ko)
*
|
2019-01-17 |
2020-03-05 |
주식회사 녹십자 |
B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
KR102890251B1
(ko)
|
2019-03-15 |
2025-11-25 |
메드임뮨 리미티드 |
암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
|
|
CN112442118B
(zh)
*
|
2019-08-30 |
2023-02-14 |
深圳普瑞金生物药业股份有限公司 |
一种tcr及其应用
|
|
CH717565A1
(fr)
|
2020-06-25 |
2021-12-30 |
Planair Sa |
Installation photovoltaïque et procédé de construction d'une telle installation.
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
US11421015B2
(en)
|
2020-12-07 |
2022-08-23 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
CN116710115A
(zh)
|
2020-11-20 |
2023-09-05 |
思维疗法股份有限公司 |
用于优化的肽疫苗的组合物和方法
|
|
US11058751B1
(en)
|
2020-11-20 |
2021-07-13 |
Think Therapeutics, Inc. |
Compositions for optimized RAS peptide vaccines
|
|
US11161892B1
(en)
|
2020-12-07 |
2021-11-02 |
Think Therapeutics, Inc. |
Method of compact peptide vaccines using residue optimization
|
|
US11464842B1
(en)
|
2021-04-28 |
2022-10-11 |
Think Therapeutics, Inc. |
Compositions and method for optimized peptide vaccines using residue optimization
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
CN116262779A
(zh)
*
|
2021-12-14 |
2023-06-16 |
深圳先进技术研究院 |
一种单细胞筛选鉴定人乳头瘤病毒特异性tcr的方法
|
|
EP4328239A1
(en)
|
2022-08-26 |
2024-02-28 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Immunotherapeutics based on magea1-derived epitopes
|
|
EP4637833A2
(en)
|
2022-12-23 |
2025-10-29 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
|
EP4698230A2
(en)
|
2023-04-17 |
2026-02-25 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
|
WO2026006688A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Degrader antibody conjugates and uses thereof
|
|
WO2026006689A2
(en)
|
2024-06-28 |
2026-01-02 |
Firefly Bio, Inc. |
Bcl-xl degrader antibody conjugates and uses thereof
|